首页|特殊人群应用伏立康唑的群体药动学研究进展

特殊人群应用伏立康唑的群体药动学研究进展

扫码查看
伏立康唑(VRC)是广谱三唑类抗真菌药物,用于成人和儿童侵袭性真菌感染(IFI)的全身预防和治疗。但VRC具有典型的非线性药代动力学特征和高度可变的个体间和个体内差异,限制其在临床的合理应用。特殊人群由于生理学原因差异更大,尤其是低龄儿童患者,在使用VRC时证据少,局限性较大。近年来越来越多的VRC群体药代动力学(PPK)研究成果发表,识别出许多协变量,这为VRC的合理使用提供思路和方法。本文根据最新的国内外研究结果,介绍VRC应用于特殊人群的PPK最新进展,并展示如何利用PPK来调整剂量和优化治疗。
Advances in population pharmacokinetics of voriconazole in special populations
Voriconazole(VRC)is a broad-spec-trum triazole antifungal drug used for the systemic prophylaxis and treatment of invasive fungal infec-tions(IFI)in adults and children.However,VRC has a typical nonlinear pharmacokinetic profile and highly variable inter-and intra-individual variability,limiting its rational clinical use.Special populations have even greater variation due to physiologic rea-sons,especially younger pediatric patients,with less evidence and greater limitations in the use of VRC.In recent years more and more VRC popula-tion pharmacokinetic(PPK)research results have been published,identifying many covariates,which provides ideas and methods for the rational use of VRC.Based on the latest national and international research results,this article introduced the latest progress of PPK of VRC applied to special popula-tions and demonstrated how PPK could be used to adjust the dose and optimize the treatment.

voriconazolepopulation pharmacoki-neticsspecial populationschildrenliver cirrhosis

杨雪容、方静、陈璐、杨勇

展开 >

成都市第六人民医院药剂科,成都 610051,四川

四川省医学科学院·四川省人民医院药学部,成都 610072,四川

电子科技大学医学院,个体化药物治疗四川省重点实验室,成都 610072,四川

伏立康唑 群体药代动力学 特殊人群 儿童 肝硬化

2024

中国临床药理学与治疗学
中国药理学会

中国临床药理学与治疗学

CSTPCD北大核心
影响因子:0.97
ISSN:1009-2501
年,卷(期):2024.29(12)